Tubulis: €128 Million Raised To Expand Therapeutic Potential Of Antibody-Drug Conjugates
By Amit Chowdhry ● Mar 15, 2024
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 funding round. This funding round was co-led by EQT Life Sciences and Nextech Invest, on behalf of one or more funds managed by it, with participation from Frazier Life Sciences and Deep Track Capital and all existing investors, such as Andera Partners, BioMedPartners, Fund+, Bayern Kapital (with ScaleUp-Fonds Bayern), Evotec, coparion, Seventure Partners, OCCIDENT and High-Tech Gründerfonds (HTGF).